Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight

View original at fool.com

Motley Fool - Stock Analysis Title: Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight Date: 2026-04-04 17:32 Source: https://www.fool.com/investing/2026/04/04/eli-lilly-stock-punch-could-knock-novo-nordisk/?source=iedfolrf0000001 <p><strong>Novo Nordisk</strong> and <strong>Eli Lilly</str…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Wegovy pill is the first GLP-1 pill for weight loss
60% confidence
Wegovy pill is the first GLP-1 pill for weight loss
60% confidence
Lilly made up ground and ultimately surpassed Novo Nordisk in the U.S.
60% confidence
Eli Lilly's one-two punch could knock Novo Nordisk out of the obesity drug fight and cement the company atop the weight-loss drug market for the foreseeable future
60% confidence
Novo Nordisk broke the anti-obesity drug market open with Ozempic
60% confidence
Eli Lilly has a one-two punch that could cement the company atop the weight-loss drug market for the foreseeable future
60% confidence
Novo Nordisk and Eli Lilly have been sparring for control of the booming anti-obesity drug market
60% confidence
Eli Lilly made up ground and ultimately surpassed Novo Nordisk in the U.S. anti-obesity drug market
60% confidence